Log in

Start Your Membership Now

On August 17, 2018, the U.S. Food and Drug Administration (FDA) announced it had granted marketing approval to the BrainsWay Deep Transcranial Magnetic Stimulation System (TMS) for treatment of obsessive compulsive disorder (OCD). Currently, this device has FDA approval for the treatment of major depressive disorder, received in 2013. This clearance represents the first ever non-invasive medical device clearance for the treatment of OCD.

The FDA reviewed data from a randomized, multi-center study of 100 people, of which 49 received treatment with the BrainsWay device and 51 received treatment with a non-working "placebo" device. Those already . . .

Want To Read More? Log In Or Become A Paid Member
Resource Available For Paid OPEN MINDS Circle Members Only
Not a paid member? Don't miss out! Sign up today and receive unlimited organizational access to all OPEN MINDS strategic advice, market intelligence, and management best practices – over 250,000 resources!
Log In
If you are already a paid member, log in to your account to access this resource and more. If you are a free member, you will need to upgrade to a paid membership before accessing this resource.

Become A Paid Member
If you are not yet a paid member, learn more about the OPEN MINDS Circle Market Intelligence Service Membership on our website, reach out to our team at info@openminds.com, or call us at 877-350-6463.

Tagged As: